1[2]Liaw YF,Chien RN,Yeh CT. et al. Acute exacerbation and hepatitisB virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology, 1999,33:567 ～ 572. 被引量：1
2Liaw YF,chien Rn, Yeh CT,Tsa SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepalology 1999:30:567-572. 被引量：1
3Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY.Fatal submassive hepatic necrosis associated with tyrosinemethionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001:33:403-405. 被引量：1
4Hendricks DA, Stowe BJ, Hoo BS, Kolberg J, Irvine BD, Neuwald PD, Urdea MS, Perrillo RP. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathal 1995:104:537-546. 被引量：1
5Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M.Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD Motif). Hepatol Res 2000:17:31-42. 被引量：1
6de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE,Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B:hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998:29:669-675. 被引量：1
7Bonacini M, Kurz A, Locamini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002:122:244-245. 被引量：1
8Malik AH, Lee WM. Hepatitis B therapy: the plot thickens. Hepatology 1999:30:579-581. 被引量：1
9Perrillo R, Schiff E. Yoshida F, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000:32:129-134. 被引量：1
10Marcellin P, Chang TT, Lim SG, Tong ML, Sievert W, Shiffman ML, Jeffers L, Goodman Z,Wulfsohn MS,Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B. N Engl J Med 2003:348:808-816. 被引量：1
2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
4Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact[J]. J Clin Virol, 2005, 32(2): 102-112. 被引量：1
5Arauz RP, Norder H, Robertson BH, et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America [J]. J Gen Virol, 2002, 83(Pt 8): 2059-2073. 被引量：1
6Li D, Gu HX, Zhang SY, et al. YMDD mutations and genotypes of hepatitis B virus in northern China [J]. Jpn J Infect Dis, 2006, 59(1): 42-45. 被引量：1
7Moskovitz DN, Osiowy C, Giles E, et al. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance [J]. J Viral Hepat, 2005, 12(4): 398-404. 被引量：1
8Yuen MF, Yuan HJ, Sablon E, et al. Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares [J]. J Clin Microbiol, 2004, 42(9): 3932-3936. 被引量：1
9Pan XP, Li LJ, Du WB, et al. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C[J]. J Viral Hepat, 2007, 14(11): 767-774. 被引量：1
10Svicher V, Gori C, Trignetti M, et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by FIBV genotypes[J]. J Hepatol, 2009, 50(3): 461-470. 被引量：1
